Home Interviews Circio’s CEO on the new strategy

Circio’s CEO on the new strategy

Erik Digman Wiklund, CEO Circio

Circio’s CEO on the new strategy

16 May, 2023

Circio, formerly known as Targovax, is a Norwegian immunotherapy company within RNA-based therapeutics. The company is focusing on circular RNA, which holds several advantages over mRNA, according to CEO Erik Digman Wiklund. The potential of circular RNA has been acknowledged by the industry, as the area is attracting a lot of interest and investments.

Watch the interview with Circio’s CEO Erik Digman Wiklund in the link below.

YouTube video

Learn more about Circio on the company’s website.

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev